GO:0031547 brain-derived neurotrophic factor receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031547 describes the molecular signal transduction cascade triggered when brain-derived neurotrophic factor (BDNF) binds to its receptor TrkB (NTRK2).
• The pathway is initiated by BDNF-induced TrkB dimerization and autophosphorylation, leading to activation of ERK1/2, PI3K-Akt, and PLC-gamma1 branches.
• BDNF-TrkB signaling is a central regulator of neuronal survival, synaptic plasticity, and mood, and is a validated target in depression and CNS injury.
• The pathway is not confined to the nervous system; it operates in colorectal cancer, kidney disease, and reproductive tissues, where it influences proliferation and survival.
• Sex differences and scaffolding proteins such as PSD-95 modulate the strength and outcome of BDNF receptor signaling.
• CRISPR-based knockout, point-mutation, and knock-in models are essential to dissect causal roles of BDNF, NTRK2, and downstream effectors in health and disease.
Description
The brain-derived neurotrophic factor receptor signaling pathway (GO:0031547) is the series of molecular events that occur after BDNF binds to its physiological receptor, TrkB (encoded by NTRK2). This pathway is a canonical neurotrophin signaling cascade that converts an extracellular growth factor cue into intracellular signals controlling neuronal survival, differentiation, synaptic plasticity, and neurotransmitter release. Because of its broad impact on nervous system function, the pathway is intensively studied in neurobiology, psychiatry, and oncology. Researchers need a precise, ontology-anchored definition of GO:0031547 to design experiments that distinguish receptor-proximal events from downstream transcriptional and structural changes. The pathway is also relevant beyond the brain: BDNF-TrkB signaling has been documented in colorectal cancer cells, kidney diseases, and endometrial Ishikawa cells, where it regulates proliferation and survival. Understanding the core molecular steps, key genes, and regulatory inputs of this pathway is therefore essential for both fundamental discovery and therapeutic development.
brain-derived neurotrophic factor receptor signaling pathway At A Glance
| GO ID | GO:0031547 |
|---|---|
| GO term | brain-derived neurotrophic factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | BDNF receptor signaling pathway; BDNF signalling pathway; brain-derived neurotrophic factor receptor signalling pathway |
| Major function | Transduces BDNF binding to TrkB into intracellular signals controlling neuronal survival, synaptic plasticity, and proliferation |
| Key receptor | TrkB (NTRK2), a receptor tyrosine kinase |
| Primary ligand | Brain-derived neurotrophic factor (BDNF) |
| Major downstream branches | ERK1/2, PI3K-Akt, and PLC-gamma1 cascades |
| Physiological contexts | CNS development, mood regulation, synaptic plasticity, and non-neuronal tissues including kidney and reproductive cells |
What Is GO:0031547?
GO:0031547 is defined in QuickGO as the series of molecular signals generated as a consequence of a brain-derived neurotrophic factor receptor binding to one of its physiological ligands. In practical terms, it encompasses ligand-induced activation of the BDNF receptor TrkB, the immediate receptor-proximal phosphorylation events, and the downstream signaling cascades that propagate the signal within the cell. The term is a biological process and is synonymous with BDNF receptor signaling pathway, BDNF signalling pathway, and brain-derived neurotrophic factor receptor signalling pathway.
Why Is brain-derived neurotrophic factor receptor signaling pathway Important in Cell Biology?
The BDNF receptor signaling pathway is one of the most studied neurotrophic cascades because it directly links extracellular growth factor availability to neuronal survival, circuit plasticity, and behavior. Dysregulation of this pathway is implicated in mood disorders, CNS injury, and cancer, making it a high-value target for both mechanistic research and therapeutic intervention. Because the pathway operates in multiple tissues and is modulated by sex and scaffolding proteins, it also serves as a model system for understanding context-dependent signaling.
• Controls neuronal survival and differentiation during development and after injury.
• Mediates antidepressant-like effects of ketamine through BDNF-TrkB signaling in mood disorders.
• Regulates synaptic plasticity and depression-like behaviors via postsynaptic scaffolding proteins such as PSD-95.
• Promotes proliferation in non-neuronal cells, including endometrial Ishikawa cells through TrkB-ERK1/2.
• Is a potential therapeutic target in colorectal cancer.
• Shows sex differences that affect signaling outcomes and disease susceptibility.
• Is implicated in kidney diseases, expanding its relevance beyond the nervous system.
• Interacts antagonistically with Nogo signaling via upregulation of LOTUS.
• Provides a tractable model for studying receptor tyrosine kinase signaling specificity.
• Offers multiple nodes for CRISPR-based functional dissection and drug discovery.
What Happens During brain-derived neurotrophic factor receptor signaling pathway?
Ligand binding and receptor dimerization
In simple terms: BDNF acts like a key that fits into the TrkB lock, causing two TrkB molecules to pair up.
The pathway begins when BDNF binds to the extracellular domain of TrkB (NTRK2), inducing receptor dimerization and activation of its intrinsic tyrosine kinase activity. This ligand-receptor interaction is the defining event of GO:0031547 and is required for all downstream signaling. In the absence of BDNF, TrkB remains largely inactive, and the pathway is not engaged.
Receptor autophosphorylation and adaptor recruitment
In simple terms: Once paired, TrkB molecules add phosphate tags to each other, creating docking sites for helper proteins.
Dimerized TrkB undergoes autophosphorylation on specific tyrosine residues within its intracellular domain, generating binding sites for adaptor proteins such as Shc, PLC-gamma1, and PI3K regulatory subunits. These phosphorylation events are the immediate receptor-proximal steps that convert ligand binding into intracellular signals. The pattern of autophosphorylation determines which downstream branches are engaged.
Activation of ERK1/2 cascade
In simple terms: A chain of kinases relays the signal to the nucleus, telling the cell to grow or survive.
One major branch of BDNF-TrkB signaling activates the Ras-MAPK-ERK1/2 cascade, which translocates to the nucleus and regulates transcription factors involved in survival, proliferation, and plasticity. In Ishikawa cells, BDNF regulates proliferation specifically through the TrkB-ERK1/2 pathway. This branch is often measured by phospho-ERK1/2 levels as a readout of pathway activity.
PI3K-Akt survival signaling
In simple terms: Another branch sends a 'stay alive' signal by activating Akt, a master survival kinase.
TrkB also recruits and activates PI3K, leading to Akt phosphorylation and inhibition of pro-apoptotic proteins. This branch is critical for neuronal survival and is frequently dysregulated in cancer and neurodegeneration. Akt activation downstream of BDNF-TrkB is a key node for therapeutic intervention.
PLC-gamma1 and calcium signaling
In simple terms: A third branch releases calcium inside the cell, influencing synaptic strength and gene expression.
TrkB activates PLC-gamma1, which hydrolyzes PIP2 to produce IP3 and DAG, leading to calcium release and PKC activation. This branch contributes to synaptic plasticity and neurotransmitter release. In depression models, modulating this pathway through PSD-95 enhances BDNF signaling and mitigates depression-like behaviors.
Crosstalk and modulation by LOTUS
In simple terms: The pathway talks to other signaling systems, and proteins like LOTUS can tune the conversation.
BDNF induces upregulation of lateral olfactory tract usher substance (LOTUS), which antagonizes Nogo signaling, demonstrating crosstalk between BDNF-TrkB and other pathways. This modulation is important for axon regeneration and synaptic reorganization. Such crosstalk expands the functional output of GO:0031547 beyond canonical neurotrophin signaling.
Key Genes Involved in GO:0031547 brain-derived neurotrophic factor receptor signaling pathway
The following genes and proteins are core components or well-documented modulators of the brain-derived neurotrophic factor receptor signaling pathway (GO:0031547).
| Gene | Major Role | Research Relevance |
|---|---|---|
| BDNF | Primary ligand that binds and activates TrkB | Central to mood disorders, synaptic plasticity, and CNS injury |
| NTRK2 (TrkB) | Receptor tyrosine kinase that initiates the pathway | Target for antidepressants, cancer, and neuroprotection |
| PSD-95 | Postsynaptic scaffolding protein that enhances BDNF signaling | Modulates depression-like behaviors in mice |
| LOTUS | Upregulated by BDNF; antagonizes Nogo signaling | Axon regeneration and synaptic reorganization |
| ERK1/2 (MAPK1/MAPK3) | Downstream kinases in the Ras-MAPK cascade | Proliferation and survival readouts in cancer and neurons |
| PI3K (PIK3CA/B) | Lipid kinase that activates Akt | Survival signaling in neurons and cancer |
| AKT1 | Serine/threonine kinase mediating survival | Key node in neuroprotection and tumorigenesis |
| PLC-gamma1 (PLCG1) | Phospholipase that generates IP3 and DAG | Calcium signaling and synaptic plasticity |
| Shc (SHC1) | Adaptor protein recruited to phospho-TrkB | Links receptor to Ras-MAPK |
| Ras (HRAS/KRAS/NRAS) | Small GTPase activating MAPK cascade | Proliferation and differentiation |
| CREB1 | Transcription factor activated downstream of ERK and Akt | Gene expression changes for survival and plasticity |
| Nogo (RTN4) | Signaling protein antagonized by BDNF-induced LOTUS | Axon regeneration |
| TrkC (NTRK3) | Related neurotrophin receptor with crosstalk | Comparative signaling studies |
| p75NTR (NGFR) | Low-affinity neurotrophin receptor modulating TrkB | Context-dependent survival vs. apoptosis |
| GRB2 | Adaptor protein linking Shc to Ras | MAPK activation |
| SOS1 | Guanine nucleotide exchange factor for Ras | Ras-MAPK activation |
| Calmodulin (CALM1/2/3) | Calcium sensor downstream of PLC-gamma1 | Calcium-dependent signaling |
How Is brain-derived neurotrophic factor receptor signaling pathway Regulated?
The BDNF receptor signaling pathway is regulated at multiple levels. Receptor availability and sensitivity are modulated by TrkB expression, trafficking, and cleavage. Sex differences influence BDNF signaling strength and outcomes, with implications for disease susceptibility. Postsynaptic scaffolding proteins such as PSD-95 enhance BDNF signaling and can be targeted to mitigate depression-like behaviors. Crosstalk with Nogo signaling via LOTUS provides an additional layer of regulation. In disease contexts such as kidney diseases, BDNF and associated signaling are dynamically regulated. These regulatory mechanisms ensure that GO:0031547 is tuned to cellular context and physiological demand.
brain-derived neurotrophic factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BDNF | Mood disorders, CNS injury | BDNF knockout mice; point-mutation knock-in of Val66Met |
| NTRK2 (TrkB) | Colorectal cancer, depression | TrkB knockout cell lines; overexpression in cancer cells |
| PSD-95 | Depression-like behaviors | PSD-95 knockout mice; knockdown in prefrontal cortex |
| LOTUS | Axon regeneration, Nogo signaling | LOTUS knockout mice; overexpression in neurons |
| ERK1/2 | Cell proliferation in cancer | ERK1/2 knockout Ishikawa cells; phospho-ERK readouts |
Mood disorders and depression
BDNF-TrkB signaling is a key mediator of antidepressant activity, including the rapid effects of ketamine in mood disorders. Enhancing BDNF signaling through modulation of PSD-95 mitigates depression-like behaviors in mice, highlighting the pathway as a therapeutic target. Sex differences in BDNF signaling may contribute to differential vulnerability to mood disorders.
CNS injury and neurodegeneration
The TrkB/BDNF signaling pathway is a focus for therapeutic intervention in CNS injury, where it promotes neuronal survival and regeneration. Small molecular agonists of TrkB are being developed to activate the pathway in injury settings. BDNF-induced LOTUS expression antagonizes Nogo signaling, supporting axon regeneration.
Cancer
TrkB/BDNF signaling is a potential therapeutic target in colorectal cancer, where it promotes proliferation and survival. In endometrial Ishikawa cells, BDNF regulates proliferation through the TrkB-ERK1/2 pathway, demonstrating its role in reproductive cancers. The pathway's involvement in multiple cancer types makes it a candidate for targeted therapy.
Kidney diseases
BDNF and associated signaling have been implicated in kidney diseases, expanding the pathophysiological relevance of GO:0031547 beyond the nervous system. The mechanisms may involve survival and proliferation signals in renal cells.
From brain-derived neurotrophic factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does BDNF-TrkB signaling drive neuronal survival? | TrkB knockout (KO) mice or neurons |
| What is the role of BDNF Val66Met polymorphism? | Point-mutation knock-in mice |
| How does PSD-95 modulate depression-like behavior? | PSD-95 knockout or knockdown mice |
| Does TrkB-ERK1/2 mediate proliferation in endometrial cells? | Ishikawa cell line with ERK1/2 KO or TrkB overexpression |
| Can LOTUS antagonize Nogo signaling? | LOTUS overexpression or knockout in neurons |
| Is BDNF-TrkB signaling a target in colorectal cancer? | Colorectal cancer cell lines with TrkB KO or overexpression |
How to Study the brain-derived neurotrophic factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phospho-TrkB, phospho-ERK1/2, phospho-Akt levels | Pathway activation after BDNF stimulation |
| RNA-seq | Transcriptional changes downstream of BDNF-TrkB | Identifying target genes and plasticity programs |
| Immunofluorescence | PSD-95 puncta, synaptic markers | Synaptic plasticity and scaffolding |
| Calcium imaging | Intracellular calcium flux | PLC-gamma1 branch activity |
| Behavioral tests | Depression-like behaviors | Functional validation in mice |
| CRISPR knockout | Loss-of-function of pathway genes | Causal gene discovery |
| Overexpression | Gain-of-function of BDNF or TrkB | Cancer and neuronal survival studies |
| Proteomics | Protein interaction networks | Identifying novel pathway components |
Phospho-protein profiling
Measuring phosphorylation of TrkB, ERK1/2, Akt, and PLC-gamma1 by Western blot or immunoassay provides a direct readout of pathway activation. Time-course experiments after BDNF stimulation reveal kinetics of each branch.
Transcriptomics and RNA-seq
RNA sequencing after BDNF stimulation or TrkB knockout identifies transcriptional programs downstream of GO:0031547. This approach can reveal CREB target genes and plasticity-related transcripts.
Imaging and synaptic assays
Live-cell imaging of synaptic markers and calcium indicators visualizes the PLC-gamma1 branch and structural plasticity. PSD-95 puncta analysis quantifies synaptic scaffolding changes.
Behavioral and functional assays
Depression-like behaviors in mice, such as forced swim or sucrose preference, assess the functional impact of BDNF signaling modulation. Motor and cognitive tests can evaluate CNS injury outcomes.
How CRISPR Can Be Used to Study GO:0031547 brain-derived neurotrophic factor receptor signaling pathway
Knockout
CRISPR knockout of BDNF, NTRK2, or downstream effectors such as ERK1/2 provides definitive loss-of-function models to test causality in GO:0031547. These models are used in neuronal cultures, cancer cell lines, and animal models to assess survival, proliferation, and behavior.
Point Mutation
Point mutations such as BDNF Val66Met can be introduced by CRISPR to model human polymorphisms and dissect their impact on receptor signaling. Such models are valuable for studying mood disorders and CNS injury.
Knock-in
Knock-in of tagged TrkB or fluorescent reporters allows real-time tracking of receptor trafficking and signaling dynamics. Knock-in of disease-associated variants in NTRK2 can reveal altered pathway activity.
Overexpression
CRISPR-mediated overexpression of BDNF or TrkB in cancer cells or neurons enhances pathway activity and models gain-of-function states. This approach is used to study proliferation in Ishikawa cells and colorectal cancer.
How EDITGENE Supports brain-derived neurotrophic factor receptor signaling pathway Research
Researchers studying brain-derived neurotrophic factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway output, disease phenotypes, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models for GO:0031547 research.
Contact EDITGENE today to design your custom CRISPR model for brain-derived neurotrophic factor receptor signaling pathway research.
Frequently Asked Questions About brain-derived neurotrophic factor receptor signaling pathway
What is the brain-derived neurotrophic factor receptor signaling pathway?
It is the series of molecular signals triggered when BDNF binds to its receptor TrkB, leading to activation of ERK1/2, PI3K-Akt, and PLC-gamma1 cascades.
What is GO:0031547?
GO:0031547 is the Gene Ontology identifier for the biological process brain-derived neurotrophic factor receptor signaling pathway.
What genes are involved in brain-derived neurotrophic factor receptor signaling pathway?
Key genes include BDNF, NTRK2 (TrkB), PSD-95, ERK1/2, PI3K, AKT1, PLCG1, and LOTUS.
How does BDNF activate TrkB?
BDNF binds to TrkB, inducing dimerization and autophosphorylation, which creates docking sites for adaptor proteins and activates downstream cascades.
What diseases are linked to BDNF-TrkB signaling?
Mood disorders, CNS injury, colorectal cancer, and kidney diseases are among the conditions linked to this pathway.
What is the role of PSD-95 in BDNF signaling?
PSD-95 is a postsynaptic scaffolding protein that enhances BDNF signaling; targeting it can mitigate depression-like behaviors in mice.
How is BDNF signaling studied in the lab?
Common methods include phospho-protein profiling, RNA-seq, imaging, behavioral assays, and CRISPR knockout or overexpression models.
What is LOTUS and how does it relate to BDNF?
LOTUS is upregulated by BDNF and antagonizes Nogo signaling, supporting axon regeneration.
Are there sex differences in BDNF signaling?
Yes, sex differences in BDNF signaling have been documented and may affect disease susceptibility and outcomes.
Can CRISPR be used to study BDNF receptor signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the pathway.
Conclusion
The brain-derived neurotrophic factor receptor signaling pathway (GO:0031547) is a central signaling cascade that translates BDNF binding to TrkB into diverse cellular outcomes, including survival, proliferation, and synaptic plasticity. Its dysregulation is implicated in mood disorders, CNS injury, cancer, and kidney diseases, making it a high-priority target for mechanistic and therapeutic research. CRISPR-based models and multi-omics approaches provide powerful tools to dissect the pathway's components and regulatory mechanisms. Continued research on GO:0031547 will advance our understanding of neurotrophin biology and enable precision interventions.
References
- 1. Wang Y et al.. 2024. TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury.. Life Sci 336:122282 PMID: 38008209
- 2. Hashimoto K. 2020. Brain-derived neurotrophic factor-TrkB signaling and the mechanism of antidepressant activity by ketamine in mood disorders.. Eur Arch Psychiatry Clin Neurosci 270(2):137-138 PMID: 32008067
- 3. Cao M et al.. 2020. Brain-Derived Neurotrophic Factor Regulates Ishikawa Cell Proliferation through the TrkB-ERK1/2 Signaling Pathway.. Biomolecules 10(12) PMID: 33302387
- 4. Akil H et al.. 2016. Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.. World J Gastroenterol 22(2):490-500 PMID: 26811602
- 5. Wei YC et al.. 2017. Sex differences in brain-derived neurotrophic factor signaling: Functions and implications.. J Neurosci Res 95(1-2):336-344 PMID: 27870405
- 6. Shi X et al.. 2024. Targeting the postsynaptic scaffolding protein PSD-95 enhances BDNF signaling to mitigate depression-like behaviors in mice.. Sci Signal 17(834):eadn4556 PMID: 38687826
- 7. Xue C et al.. 2026. Brain-Derived Neurotrophic Factor and Associated Signaling in Kidney Diseases.. FASEB J 40(13):e72113 PMID: 42394379
- 8. Matsubayashi J et al.. 2023. Brain-derived neurotrophic factor (BDNF) induces antagonistic action to Nogo signaling by the upregulation of lateral olfactory tract usher substance (LOTUS) expression.. J Neurochem 164(1):29-43 PMID: 36448220
